United Therapeutics has invested in the transplanted organ monitoring system developer as part of a collaboration agreement.
Tai Diagnostics, a US-based developer of organ transplant aftercare technology, closed a $10m series A round featuring biopharmaceutical company and strategic partner United Therapeutics on Monday.
Founded in 2015, Tai Diagnostics is working on a monitoring procedure for patients who have undergone an organ transplant.
Tai’s approach specifically identifies the transferred DNA that has been damaged, potentially acting as a more reliable indicator of organ rejection than the tissue biopsies often used today.
The funding will go to research and development…
